Nurix Therapeutics, Inc. (NRIX) Discusses Clinical Data and Pipeline Update for BTK Degrader Program Bexobrutideg December 8, 2025 8:15 PM EST
Company Participants
Arthur Sands - CEO, President & Director Paula O’Connor - Chief Medical Officer Gwenn Hansen - Chief Scientific Officer
Conference Call Participants
Alvaro Jose Alencar Jiale Song - Jefferies LLC, Research Division Christopher Liu - Lucid Capital Markets, LLC, Research Division Gil Blum - Needham & Company, LLC, Research Division Matthew Biegler - Oppenheimer & Co. Inc., Research Division Sudan Loganathan - Stephens Inc., Research Division Stephen Willey - Stifel…
Nurix Therapeutics, Inc. (NRIX) Discusses Clinical Data and Pipeline Update for BTK Degrader Program Bexobrutideg December 8, 2025 8:15 PM EST
Company Participants
Arthur Sands - CEO, President & Director Paula O’Connor - Chief Medical Officer Gwenn Hansen - Chief Scientific Officer
Conference Call Participants
Alvaro Jose Alencar Jiale Song - Jefferies LLC, Research Division Christopher Liu - Lucid Capital Markets, LLC, Research Division Gil Blum - Needham & Company, LLC, Research Division Matthew Biegler - Oppenheimer & Co. Inc., Research Division Sudan Loganathan - Stephens Inc., Research Division Stephen Willey - Stifel, Nicolaus & Company, Incorporated, Research Division Gregory Renza - Truist Securities, Inc., Research Division Tessa Romero - JPMorgan Chase & Co, Research Division Biren Amin - Piper Sandler & Co., Research Division Joseph Catanzaro - Mizuho Securities USA LLC, Research Division
Presentation
Arthur Sands CEO, President & Director
Good evening, everyone. My name is Arthur Sands. I’m President and CEO of Nurix Therapeutics. And I’d like to welcome you to our 2025 Investor and Analyst event broadcasting here from Orlando, Florida after – well, still in the midst of a terrific ASH, but getting near the end, but a lot of exciting new information at ASH this year, not only for our programs, but many others that are relevant to the incredible opportunities to improve therapies for patients with CLL and many other diseases covered here. So really absolutely terrific meeting.
So we’re very excited to have you all tonight, and I’ll be making a few opening remarks, and then we’re going to dive – do a deep dive into our data that was presented here today. We’re very fortunate to have Dr. Alencar here from University of Miami, who will be presenting the data, a fantastic expert in the field, one of our key investigators. We’re very excited to have you. Thank you, Dr. Alencar. And then we’ll have our Chief Medical Officer, Paula O’Connor, talk to us about our development program for